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 ARTHROPLASTY
Personalized estimation of one- year 
mortality risk after elective hip or knee 
arthroplasty for osteoarthritis
JOiNtCaLC MOdEL dEVELOpMENt aNd VaLidatiON usiNg thE 
NatiONaL JOiNt REgistRy aNd thE NORWEgiaN aRthROpLasty 
REgistER
Aims
To develop and validate patient- centred algorithms that estimate individual risk of death 
over the irst year after elective joint arthroplasty surgery for osteoarthritis.
Methods
A total of 763,213 hip and knee joint arthroplasty episodes recorded in the National Joint 
Registry for England and Wales (NJR) and 105,407 episodes from the Norwegian Arthro-
plasty Register were used to model individual mortality risk over the irst year after sur-
gery using lexible parametric survival regression.
Results
The one- year mortality rates in the NJR were 10.8 and 8.9 per 1,000 patient- years after 
hip and knee arthroplasty, respectively. The Norwegian mortality rates were 9.1 and 6.0 
per 1,000 patient- years, respectively. The strongest predictors of death in the inal mod-
els were age, sex, body mass index, and American Society of Anesthesiologists grade. 
Exposure variables related to the intervention, with the exception of knee arthroplasty 
type, did not add discrimination over patient factors alone. Discrimination was good in 
both cohorts, with c- indices above 0.76 for the hip and above 0.70 for the knee. Time- 
dependent Brier scores indicated appropriate estimation of the mortality rate (≤ 0.01, all 
models).
Conclusion
Simple demographic and clinical information may be used to calculate an individualized estimation 
for one- year mortality risk after hip or knee arthroplasty (https:// jointcalc. shef. ac. uk). These models 
may be used to provide patients with an estimate of the risk of mortality after joint arthroplasty.
Cite this article: Bone Joint Res 2020;9(11):808–820.
Keywords: Mortality, Flexible parametric survival model prediction, Joint arthroplasty, Calibration, discrimination
Article focus
 death is an uncommon but important 
outcome after joint arthroplasty to which 
several factors contribute.
 to enable patients to come to an informed 
decision among the treatment choices, 
these risks must be personalized according 
to the patient’s own circumstances.
 Validated patient decision support tools 
that quantify this risk in an easily acces-
sible form are lacking.
Key messages
 We have developed and validated 
prediction models that underpin a web- 
enabled, patient- centred tool to provide 
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patients considering surgery an individualized esti-
mation of outcomes after hip or knee arthroplasty.
 simple models containing basic demographic and 
comorbidity data provide a similar quality of mortality 
estimation to more complex models that include 
modiiable variables associated with the choice of 
intervention.
 these same models provide similar discrimination 
when applied to another country, despite diferences 
in mortality rates.
Strengths and limitations
 these models were developed using the world’s 
largest joint arthroplasty register and validated in 
another long- established national register.
 the models were developed using observational data 
in patients who have undergone these procedures.
 in places where the data distribution is sparse, such 
as at the extremes of age and body mass index, the 
estimates are less robust.
Introduction
patients considering any medical intervention need to 
be able to understand the potential risks and beneits of 
the diferent treatment options available. the use of deci-
sion support instruments can help patients to be better 
informed when making these choices.1-3 these instruments 
may provide generic information based on aggregate data, 
or more personalized information using algorithms that 
are tailored to the individual patient’s characteristics and 
the proposed intervention.4-6 personalized instruments are 
more complex to construct than generic ones and require 
data gathered from a population of suicient size, and with 
suicient diversity of input and output variables to provide 
a statistically meaningful estimation of the outcomes.7,8
death is an uncommon but important outcome after 
routine joint arthroplasty surgery, with 90- day mortality 
estimated in recent systematic reviews to be 0.65% (95% 
conidence interval (Ci) 0.50 to 0.81) and 0.39% (95% Ci 
0.32 to 0.49) after total hip or knee arthroplasty, respec-
tively.9,10 Older age, male sex, and pre- existing comor-
bidities are associated with a higher risk of death after 
surgery.11-16 Modiiable variables related to the choice of 
intervention such as surgical approach, use of thrombo-
prophylaxis, and implant selection are also associated with 
the mortality outcome.11,12,17
We recently reported the development of the irst 
comprehensive web- based personalized decision 
support tool for patients considering hip arthroplasty 
(https:// jointcalc. shef. ac. uk).7,18,19 this tool was devel-
oped in partnership with patients to enable them to 
come to an informed decision about the risks and bene-
its of surgery. here, we describe the development and 
validation of the tool’s underlying personalized models 
that generate absolute predicted risk of death over the 
irst year after hip or knee arthroplasty using demo-
graphic, prosthesis, and procedure- related data from 
the National Joint Registry for England and Wales (NJR). 
the external generalizability of the prediction models 
was tested using cohort data from the Norwegian 
arthroplasty Register (NaR).
Methods
Participating cohorts. the NJR cohort comprised in-
dividuals undergoing primary total hip and knee 
arthroplasty procedures between april 2003 and 
december 2015. NJR episode data for all patients are 
linked to death event and date through the National 
patient demographics service of the Oice for National 
statistics. the NaR cohort dataset comprised primary 
total hip and knee arthroplasty procedures performed 
between January 2005 and december 2016. the 
Norwegian National Registry provided dates of death 
for all patients. For both cohorts we included proce-
dures where osteoarthritis was the only indication for 
surgery and included only those patients with complete 
demographic records. all NJR analyses were carried out 
using stata 15 (stataCorp, College station, texas, usa). 
the NaR cohort was analyzed independently using R 
version 3.5.1 (R Foundation for statistical Computing, 
Vienna, austria).
Modelling. We analyzed hip and knee arthroplasty pro-
cedures separately. person- time incidence mortality 
rates per 1,000 patient- years were calculated separately 
for hip and knee procedures. We used lexible paramet-
ric survival regression (FpR) to model absolute mortal-
ity in the irst year after surgery, due to its ability to 
estimate absolute risk in addition to relative risk.20 FpR 
uses restricted cubic splines to provide a lexible spec-
iication of the baseline hazard. For each joint type we 
considered two models: a ‘community- based’ version 
intended for use by the patient on any web- enabled 
device; and a ‘clinic- based’ version intended for com-
pletion by the patient with the support and input of a 
clinician. the clinic- based version includes modiiable 
variables related to the intervention, relecting the addi-
tional choice information available in the clinic setting.
in the community- based hip model we considered 
age, sex, body mass index (BMi), and american society 
of anesthesiologists (asa) physical status grade21,22 
as covariates. For the clinic- based hip model we also 
included surgical approach, prosthesis ixation type, 
prosthesis- bearing materials, and diameter, anaes-
thetic, chemical, and mechanical thromboprophy-
laxis choices. in the community- based knee model we 
considered age, sex, BMi, and asa grade as covariates. 
For the clinic- based knee model we also included pros-
thesis type (total, unicompartmental, or patellofem-
oral), anaesthetic choice, and chemical and mechanical 
thromboprophylaxis options. details of the model 
speciication and development are described in detail 
in the supplementary Material.
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Fig. 1
patient low chart for inclusion in the National Joint Registry for England and Wales (NJR) models. asa, american society of anaesthesiologists; BMi, body 
mass index.
Internal validation. We compared the agreement to the 
observed data using graphical methods and calculated 
metrics to assess the accuracy and discriminative ability 
of the models. We used internal cross- validation to cal-
culate model performance metrics and calibration plots 
to visually assess model it. We graphically compared 
the mean predicted survival from the chosen model to 
Kaplan- Meier estimates of mortality from the NJR with-
in ive prognostic groups, based on quintiles of the pre-
dicted risk. if a model shows good it to the data then 
the predicted mortality curves should be in close agree-
ment with the Kaplan- Meier curves.
harrell’s concordance index (c- index) was used to 
assess the discrimination ability of the models. the 
c- index describes the proportion of all possible pairs of 
procedures where the procedure in the pair with the 
shortest observed survival time has a higher predicted 
risk.23 the c- index can range between 0 and 1, where a 
value of 0.5 indicates random assignment and values 
closer to 1 indicate positive discriminative ability, analo-
gous to the area under a receiver operator characteristic 
curve. We calculated the c- index using somersd 
command in stata, with adjustment for censoring.23,24 
We used ive- fold cross validation for our internal model 
validation, repeated 50 times, to calculate the above 
performance metrics with 95% Cis. time- dependent 
Brier scores were used to evaluate overall predictive 
ability of our survival models.25 the Brier score is the 
mean squared diference between the actual outcome 
and predicted probability of that outcome at a given 
time. the Brier score can range between 0 and 1, where 
values closer to 0 indicate better predictive accuracy. 
We calculated time- dependent Brier scores, adjusted 
for censoring using Kaplan- Meier based censoring 
weights,26 at 1, 3, 6, 9, and 12 months.
External validation. to assess the generalizability of our 
models, we carried out external validation using data 
on primary hip and knee arthroplasties from the NaR. 
information on BMi, anaesthetic type, and mechan-
ical thromboprophylaxis are not recorded in the NaR 
and therefore these variables were excluded from the 
external validation models. in addition, as either low 
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Table I. demographic and surgical characteristics for National Joint Registry for England and Wales (NJR) hip and knee arthroplasty procedures included in 
the models.
Characteristic Hip arthroplasty procedures Knee arthroplasty procedures
N % Deaths, n* PTIR† N %
Deaths, 
n* PTIR†
all 340,033 100.0 3,368 10.8 423,180 100.0 3,458 8.9
Age, yrs
  30 to 40 1,697 0.5 2 1.3 581 0.1 1 1.8
  40 to 50 10,851 3.2 19 1.9 10,047 2.4 13 1.4
  50 to 60 42,948 12.6 107 2.7 56,550 13.4 117 2.2
  60 to 70 107,642 31.7 526 5.3 145,547 34.4 548 4.1
  70 to 80 125,281 36.8 1,304 11.3 153,420 36.3 1,397 9.9
  80 to 90 49,169 14.5 1,263 28.2 55,160 13.0 1,261 25.0
  90 to 100 2,445 0.7 147 67.2 1,875 0.4 121 72.4
Sex
  Female 207,231 60.9 1,718 9.0 239,275 56.5 1,542 7.0
  Male 132,802 39.1 1,650 13.5 183,905 43.5 1,916 11.3
ASA class
  1 48,480 14.3 149 3.3 47,162 11.1 143 3.3
  2 241,695 71.1 1,867 8.4 311,003 73.5 2,117 7.4
  3 48,588 14.3 1,242 28.2 63,857 15.1 1,130 19.4
  4 1,270 0.4 110 98.1 1,158 0.3 68 64.5
BMI, kg/m2
  15 to 18.5 2,467 0.7 88 39.2 785 0.2 19 26.1
  18.5 to 25 74,010 21.8 928 13.6 47,373 11.2 635 14.5
  25 to 30 136,077 40.0 1,287 10.3 149,620 35.4 1,296 9.4
  30 to 40 117,169 34.5 977 9.1 199,058 47.0 1,336 7.3
  40 to 55 10,310 3.0 88 9.4 26,344 6.2 172 7.1
Chemical 
thromboprophylaxis
  None 12,388 3.6 120 9.9 20,117 4.8 181 9.1
  aspirin only 21,628 6.4 246 11.9 32,833 7.8 315 10.0
  heparin (± aspirin) 216,978 63.8 2,159 10.8 266,795 63.0 2,151 8.7
  Other 86,086 25.3 796 10.4 98,806 23.3 760 8.6
  Missing 2,953 0.9 47 16.1 4,629 1.1 51 11.1
Mechanical 
thromboprophylaxis
  None 17,268 5.1 194 11.8 20,427 4.8 192 9.9
  active‡ 82,455 24.2 802 10.7 93,535 22.1 739 8.7
  passive§ 102,255 30.1 1,057 11.2 134,530 31.8 1,127 9.0
  Both 124,504 36.6 1,169 10.2 164,671 38.9 1,295 8.6
  Other 9,555 2.8 94 10.3 5,741 1.4 42 7.7
  Missing 3,996 1.2 52 13.1 4,276 1.0 63 14.8
Anaesthetic
  general only 69,641 20.5 680 10.6 82,963 19.6 598 7.8
  Regional only 203,492 59.8 2,025 10.9 263,413 62.2 2,233 9.3
  general and regional 66,315 19.5 656 10.5 75,869 17.9 612 8.5
  Missing 585 0.2 7 12.1 935 0.2 15 16.2
Knee type
  total 380,440 89.9 3,309 9.4
  unicompartmental 37,999 9.0 130 4.3
  patello- femoral 4,741 1.1 19 3.7
Hip fixation
  Cemented 119,387 35.1 1,589 14.4
  uncemented 137,149 40.3 967 7.6
  hybrid 69,025 20.3 652 10.5
  Reverse hybrid 9,209 2.7 100 11.9
  Missing 5,263 1.5 60 11.8
Continued
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Characteristic Hip arthroplasty procedures Knee arthroplasty procedures
N % Deaths, n* PTIR† N %
Deaths, 
n* PTIR†
Hip bearing
  Mop 217,310 63.9 2,744 13.7
  CoC 60,496 17.8 264 4.6
  Cop 58,642 17.2 311 6.0
  Missing 3,585 1.1 49 14.0
Femoral head size, mm
  < 32 153,638 45.2 1,728 11.9
  32 104,481 30.7 944 10.2
  > 32 79,645 23.4 664 9.1
  Missing 2,269 0.7 32 14.5
Surgical approach
  posterior 132,686 39.0 1,468 11.8
  Other 207,347 61.0 1,900 10.1
*Observed deaths up to one year after surgery.
†ptiR: person- time incidence rate (mortality rate) per 1,000 patient- years.
‡Foot pump and/or calf compression.
§thromboembolic disease stockings.
asa, american society of anesthesiologists; BMi, body mass index; CoC, ceramic on ceramic; Cop, ceramic on polyethylene; Mop, metal on 
polyethylene.
Table I. Continued
molecular weight heparin or aspirin are used almost 
universally for orthopaedic surgery chemical thrombo-
prophylaxis in Norway, the models were not adjusted 
for other anticoagulants. We calculated person- time 
incidence mortality rates per 1,000 patient- years for 
hip and knee procedures in the registry separately. We 
calculated c- index and time- dependent Brier scores us-
ing R functions survConcordance and pec, respective-
ly. We also generated calibration plots comparing NJR 
model based predicted mortality versus the observed 
mortality for patients in the NaR. as further exploratory 
analyses, hybrid models were also generated using the 
Norwegian baseline hazard together with the English 
coeicients (see supplementary Material for details).
this study was approved by the Research Commit-
tees of the NJR and the NaR. individual consent from 
subjects was not required, in accordance with data 
processing laws for pseudo- anonymized data in these 
countries.
Results
Participating cohorts. the initial NJR dataset includ-
ed 768,385 linkable hip arthroplasty procedures and 
839,192 linkable knee arthroplasty procedures with 
consent for analysis. after application of our inclusion 
and exclusion criteria (Figure 1), there were 340,033 hip 
arthroplasty procedures with the diagnosis of primary 
osteoarthritis available for complete case analysis, with 
3,368 deaths observed within the irst year after sur-
gery. there were 423,180 knee arthroplasty procedures 
with the diagnosis of primary osteoarthritis available 
for complete case analysis, with 3,458 deaths within 
the irst year after surgery. information on demograph-
ic and surgical characteristics is provided in table i for 
the included procedures. the overall incidence rate for 
mortality was 10.8 per 1,000 patient- years for hip ar-
throplasty procedures and 8.9 per 1,000 patient- years 
for knee arthroplasty procedures.
the initial NaR dataset included 207,936 linkable 
hip arthroplasty procedures and 89,689 linkable knee 
arthroplasty procedures with consent for analysis. 
after application of our inclusion and exclusion criteria 
(Figure  2), there were 60,814 hip arthroplasty proce-
dures with the diagnosis of primary osteoarthritis 
available for complete case analysis, with 524 deaths 
observed within the irst year after surgery. there were 
44,593 knee arthroplasty procedures with the diag-
nosis of primary osteoarthritis available for complete 
case analysis, with 251 deaths within the irst year after 
surgery. information on demographic and surgical 
characteristics are provided in table ii for the included 
procedures. the overall incidence rate for mortality was 
9.1 per 1,000 patient- years for hip arthroplasty proce-
dures and 6.0 per 1,000 patient- years for knee arthro-
plasty procedures.
Modelling of mortality after hip arthroplasty. a propor-
tional hazards model with four degrees of freedom for 
the spline terms was selected to model mortality after 
hip arthroplasty (see supplementary Material). the 
strongest predictors of death in the inal models were 
age, sex, BMi, and asa grade. Covariate efects for the 
inal hip models are presented in the supplementary 
Material.
Risk prediction model. the models are built using lexible 
parametric regression with four degrees of freedom. all 
NJR models use the coeicients age, sex, asa, and BMi. 
the NaR does not register height and weight so they were 
unable to use BMi in their models. the clinic- based NJR 
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Fig. 2
patient low chart for inclusion in the Norwegian arthroplasty Register (NaR) model validation.
models use an expanded coeicient set, adding chemi-
cal thromboprophylaxis, mechanical thromboprophylax-
is, and anaesthetic choice. the clinic- based hip models 
also look at hip ixation, hip bearing, femoral head size, 
and surgical approach, while the clinic- based knee mod-
els add knee type. Mechanical thromboprophylaxis and 
anaesthetic choice are not registered in the NaR data, and 
are thus excluded from the NaR models. the age variable 
is transformed according to the formula presented in the 
supplementary Material.
the hazard is then calculated using formula 1:
 hazard = βt ∗ ecoefficient score 
Where  βt  is the baseline hazard of mortality after an 
operation given for  t years, and the coeicient score is 
calculated by adding up the coeicient values for each 
patient. hazard ratios for all coeicients are presented in 
the supplementary Material. One- year mortality is calcu-
lated using formula 2:
 1 year mortality = 1− e
−
1́
t=0
hazard
 
three examples are given here: 1) a 30- year- old female, 
height 1.60 m and weight 65 kg (BMi 25.4 kg/m2), and 
with no comorbidities (asa 1) using the community- 
based NJR mortality model has a one- year risk of death 
after hip arthroplasty of 0.035%; 2) a 65- year- old male, 
height 1.80 m and weight 140 kg (BMi 43.2 kg/m2), with 
comorbidities (asa 3) using the community- based NJR 
mortality model has a one- year risk of death after hip 
arthroplasty of 1.4%; and 3) a 90- year- old male, height 
1.80 and weight 75 kg (BMi 23.1 kg/m2), with mild 
comorbidities (asa 2) using the clinic- based NJR mortality 
model, and undergoing a total knee arthroplasty under 
spinal anaesthetic using as heparin chemical but no 
mechanical thromboprophylaxis has a one- year mortality 
risk of 4.8%. the same individual undergoing a unicom-
partmental knee arthroplasty, but with the other inter-
vention choices held constant has a one- year mortality 
risk of 3.2%.
Model validation. Figure 3 shows calibration plots compar-
ing predicted mortality with Kaplan- Meier estimates from 
NJR data by quintile of predicted risk. these plots show that 
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Table II. demographic and surgical characteristics for Norwegian arthroplasty Register (NaR) hip and knee arthroplasty procedures included in models.
Characteristic Hip arthroplasty procedures Knee arthroplasty procedures
N % Deaths, n* PTIR† N % Deaths, n* PTIR†
all 60,814 100.0 524 9.1 44,593 100.0 251 6
Age, yrs
  30 to 39 141 0.2 0 0 46 0.1 0 0
  40 to 49 1,506 2.5 1 0.7 1,103 2.5 1 1
  50 to 59 7,315 12 10 1.5 6,195 13.9 9 1.5
  60 to 69 20,165 33.2 79 4.1 15,931 35.7 43 2.9
  70 to 79 22,418 36.9 189 9 16,101 36.1 111 7.4
  80 to 89 8,913 14.7 209 24.9 5,122 11.5 83 17.1
  90 to 99 356 0.6 36 113.3 95 0.2 4 46.2
Sex
  Male 20,629 33.9 246 12.7 16,767 37.6 113 7.2
  Female 40,185 66.1 278 7.3 27,826 62.4 138 5.2
ASA class
  1 11,707 19.3 34 3 6706 15 16 2.5
  2 38,171 62.8 229 6.4 29,480 66.1 126 4.6
  3 10,782 17.7 244 24.1 8,339 18.7 106 13.6
  4 154 0.3 17 125.8 68 0.2 3 47.5
Chemical 
thromboprophylaxis
  Other 5,303 8.7 44 9 3,830 8.6 14 4.1
  heparin (± aspirin) 55,362 91 479 9.1 40,671 91.2 236 6.1
  aspirin only 144 0.2 1 8.6 91 0.2 1 13.7
  None 5 0 0 0 1 0 0 0
Knee type
  total 39,099 87.7 236 6.4
  unicompartmental 5,303 11.9 15 3
  patello- femoral 191 0.4 0 0
Hip fixation
  Cemented 26,121 43 325 12.9
  uncemented 13,870 22.8 61 4.8
  hybrid 1,260 2.1 8 7.6
  Reverse hybrid 19,563 32.2 130 7.1
Hip bearing
  Mop 41,558 68.3 416 10.6
  CoC 2,553 4.2 9 3.7
  Cop 16,703 27.5 99 6.2
Femoral head size, mm
  < 32 33,050 54.3 323 9.9
  32 24,530 40.3 178 8.1
  > 32 3,234 5.3 23 7.8
Surgical approach
  Other 39,976 65.7 386 10
  posterior 20,838 34.3 138 7.3
*Observed deaths up to one year after surgery.
†ptiR: person- time incidence rate (mortality rate) per 1,000 patient- years.
asa, american society of anesthesiologists; CoC, ceramic on ceramic; Cop, ceramic on polyethylene; Mop, metal on polyethylene.
both the community- based and clinic- based models esti-
mated mortality well across all risk quintiles, with a small 
tendency to underestimate risk in the > 80th quintile, and to 
slightly overestimate risk for the other quintiles. the internal 
cross- validation based c- index was 0.762 (95% Ci 0.762 to 
0.762) for the community- based model and 0.762 (95% Ci 
0.761 to 0.762) for the clinic- based model, indicating simi-
lar discrimination ability for both. the Brier scores for both 
community- based and clinic- based models were ≤ 0.01 
(95% Ci 0.01 to 0.01) at 12 months, indicating overall good 
estimation that weakened with increasing time after surgery 
(see supplementary Material).
Figure  4 shows that the observed NaR data map into 
similar risk quintiles as the NJR internal validation dataset, 
indicating that the populations as a whole behave similarly. 
the external validation c- index was 0.787 (95% Ci 0.762 to 
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Fig. 3
Calibration plots comparing predicted mortality by risk quintile from community- based and clinic- based lexible parametric survival regression (FpR) models 
to Kaplan- Meier estimates of observed mortality after hip arthroplasty in the National Joint Registry for England and Wales (NJR).
0.812) for the community- based model and 0.785 (95% Ci 
0.761 to 0.810) for the clinic- based model, indicating similar 
discrimination ability for both. the Brier scores remained 
small for both models (≤ 0.009 (95% Ci 0.009 to 0.009) at 12 
months, see supplementary Material), indicating that they 
do not overestimate mortality within one year. Collectively, 
these data indicate that the NJR model is able to estimate 
one- year mortality risk in the NaR population.
to explore further the diferences in mortality predic-
tion between the NJR models and NaR hip dataset, we 
generated hybrid models where baseline hazards were 
exchanged between NJa and NaR mortality models. 
this exercise demonstrated a diference in the explan-
atory efects of the covariates of the hip models, indi-
cating that the patients with referent risk characteristics 
are more divergent from the other subgroups in the 
NaR data than they are in the NJR data (see supplemen-
tary Material). as the baseline hazard is also lower in 
the NaR model, the referent hip patient is less likely to 
die within one year than the referent patient in the NJR 
data. however, as the one- year mortality risk proiles 
separate into similar quintiles, we observe that the 
populations, as a whole, behave similarly within the 
two datasets.
Modelling of mortality after knee arthroplasty. 
proportional hazards models with four degrees of free-
dom for the spline terms were selected for the knee 
mortality models (see supplementary Material). the 
strongest predictors of death in the inal models were 
age, sex, BMi, asa grade, and knee arthroplasty type. 
Covariate efects for the inal knee models are presented 
in the supplementary Material.
Model validation. Figure 5 shows calibration plots com-
paring predicted mortality with Kaplan- Meier estimates 
from NJR by quintile of predicted risk. these plots 
show that both the community- based and clinic- based 
models estimated mortality well across all risk groups, 
with a small tendency to underestimate risk in the > 
80th quintile and overestimate in the others. the inter-
nal cross- validation c- index was 0.760 (95% Ci 0.759 
to 0.761) for the community- based knee model and 
0.760 (95% Ci 0.760 to 0.761) for the clinic- based knee 
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Fig. 4
Calibration plots comparing observed (Kaplan- Meier) versus predicted mortality by risk quintile for community- based and clinic- based hip models in 
Norwegian arthroplasty Register (NaR) external validation.
model, indicating similar discrimination ability. the 
Brier scores for both models were ≤ 0.01 (95% Ci 0.01 
to 0.01) at 12 months, indicating overall good estima-
tion that weakened with increasing time after surgery 
(see supplementary Material).
Figure  6 shows that the NaR data separates into 
quintiles with lower risk of death compared to that 
predicted by the NJR mortality models. this is also seen 
in table  ii, showing that the person- time incidence 
rate (mortality rate) per 1,000 patient- years (ptiR) for 
mortality in the NaR knee patients is lower than that 
in the NJR (6.0 vs 8.9 per 1,000 patient- years). this 
resulted in an overestimation of the mortality risk in the 
higher risk quintiles. the values for the external valida-
tion c- index were slightly poorer than observed for the 
internal validation, but still showed good discrimina-
tion (community- based c- index = 0.744 (95% Ci 0.708 
to 0.779), clinic- based c- index = 0.744 (95% Ci 0.709 to 
0.781)). the external validation Brier scores remained 
small for both models (≤ 0.006 (95% Ci 0.006 to 0.006) 
at 12 months, see supplementary Material), indi-
cating that they do not overestimate mortality within 
one year. Collectively, these indings indicate that the 
English model has a strong predictive ability for one- 
year mortality in knee patients in the NaR data.
to explore further the diferences in mortality predic-
tion between the NJR models and the dataset, we 
generated hybrid models where baseline hazards were 
exchanged between NJR and NaR mortality models. 
here, we observed that the patients with the referent risk 
characteristics behaved similarly within the two popu-
lations, such that neither the exchange of the baseline 
hazards nor the coeicients showed any meaningful 
diference in the predictive ability of the models (see 
supplementary Material). Comparisons of the ptiRs in 
tables i and ii indicate that the highest risk patients in 
the NJR have a higher mortality rate than the highest 
risk patients in the NaR data. thus, the mortality rate 
in the observed 80th quintile will be lower in the NaR 
data, as there are fewer patients dying overall. We can 
then infer that the NJR model will likely overestimate 
mortality in this subset of patients, as it was built on a 
higher mortality- rate population. this inference aligns 
with the observed data in Figure 6, where the NJR model 
overestimates mortality in the highest- risk patients.
Discussion
We used linked NJR and death data to generate models for 
personalized mortality estimation after joint arthroplasty 
surgery. We found that both the community- based and 
the clinic- based models were well- calibrated and showed 
good discrimination for mortality risk over one year 
following surgery. the models also validated well against 
external data from the NaR, despite underlying diferences 
in mortality rates between the countries. the similarity of 
the calibration plots between the community- based and 
the clinic- based models also suggest that use of addition of 
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Fig. 5
Calibration plots comparing predicted mortality by risk quintile from community- based and clinic- based lexible parametric survival regression (FpR) models 
to Kaplan- Meier estimates of observed mortality after knee arthroplasty in the National Joint Registry for England and Wales (NJR).
modiiable intervention- related variables, with the excep-
tion of knee arthroplasty type, does not add to diferen-
tial mortality risk prediction above basic demographic 
factors and comorbidity, as deined here by the asa score. 
although modiiable variables related to the interven-
tion afect mortality at population level,11-13 our indings 
suggest that their efect size is insuicient to inluence 
outcome for individual decision- making, apart from the 
choice between unicompartmental or total knee arthro-
plasty.17 One possible explanation for this observation is 
that these variables are associated with patient character-
istics and therefore explain a proportion of the variability 
in the clinic- based model.13,17 however, these variables do 
inluence other clinical outcomes of interest to patients in 
the decision- making process that justiies their inclusion in 
the model.7
Implications for future research. although our observation 
of diferent mortality rates between the NJR and NaR pa-
tients did not adversely afect the estimation value of the 
models, it does suggest structural diferences in the pa-
tient populations undergoing joint arthroplasty surgery 
between the countries. in support of this concept, in 2017 
life expectancy in the uK for women was 82.9 years and 
79.2 years for men, while in Norway it was 84.3 years and 
80.9 years, respectively. the death rate in the uK in 2018 
was 9.382 per 1,000, and in 2017 was 9.314 per 1,000 peo-
ple, a 0.72% increase from 2016. in contrast, the death rate 
for Norway in 2018 was 7.998 per 1,000 people, and in 
2017 was 8.038 per 1,000, a 0.5% decline from 2016.
the NJR is the world’s largest register of joint arthro-
plasty procedures and their outcomes, with completeness 
of reporting of ~95% for primary joint arthroplasty.27 as 
mortality information was obtained from linking to the 
Oice for National statistics, it is also likely to be reliable. 
the statistical model used allows a lexible speciication of 
baseline hazard and for the incorporation of non- linear and 
non- proportional covariate efects. the principal reason 
for exclusion from the analysis was missing BMi data. this 
limitation may be addressed using imputation methods.28,29 
however, as no independent BMi- related variables are 
collected, the results from such imputation are likely to be 
similar to those presented here.12 the external validation is 
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Fig. 6
Calibration plots comparing observed (Kaplan- Meier) versus predicted mortality by risk quintile for community- based and clinic- based knee models in the 
Norwegian arthroplasty Register (NaR) external validation.
based on data from the NaR, with high completeness of 
reporting of primary joint arthroplasties and deaths. the 
completeness of reporting for the years 2008 to 2016 was 
97% for both hip and knee arthroplasty.30
there were a number of strengths and limitations in this 
study. Our models were generated using observational data 
among patients who have undergone joint arthroplasty, 
and therefore exclude the sickest patients who may not be 
considered for an elective procedure. this is evidenced by 
other indings that individuals who undergo joint arthro-
plasty surgery tend to have a lower mortality rate than the 
age- and sex- matched general population.31,32 We used the 
asa grade as a simple measure of comorbidity rather than 
more complex methods, such as the Charlson Comorbidity 
index.33 previous studies indicate that the asa score closely 
correlates with the Charlson Comorbidity index across a 
range of musculoskeletal diseases, and is thus likely to be 
similarly discriminatory.34–37 We used a survivorship model-
ling approach. given the short time horizon studied and the 
lack of patient censoring, an alternative approach would 
have been to treat the problem as one of logistic regression. 
Not all variables included in the NJR models were available 
in the NaR, therefore our external validation was carried 
out using adapted models that may have afected model 
performance.
in conclusion, we have constructed models to predict 
mortality risk over the irst year after primary hip or knee 
arthroplasty. Overall, the risk of one- year mortality is 
generally low. the models show good it and predictive 
ability for survival probabilities for the uK population, and 
also comprise a model structure that is generalizable to 
the Norwegian population. although a model from one 
national cohort may be used to estimate risk in another, 
model discrimination and calibration is optimal when 
generated using data from the same cohort. these models 
may be incorporated into patient- centred decision support 
tools to better inform patients of the risks and beneits of 
joint arthroplasty surgery.19
Supplementary material
  the supplementary material ile includes: the 
general model speciication and developmental 
methods; National Joint Registry for England and 
Wales (NJR) mortality models after hip arthroplasty and 
their validation; modelling mortality after hip arthroplas-
ty using the Norwegian arthroplasty Register (NaR) data-
set; NJR mortality models after knee arthroplasty and 
their validation; and modelling mortality after knee ar-
throplasty using the NaR dataset. the ile also includes 
accompanying tables and igures for these models and 
their validation.
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